BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem ...

Presentation Will Describe the Future of Aging Research and iTRTM, an Emerging Area of Research from BioTime

Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to Extend the Healthy Lifespan”

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a Plenary Presentation at the World Stem Cell Summit at the Palm Beach County Convention Center in West Palm Beach, Florida.

In Dr. West’s presentation, “The Future of Human Aging: Implications of Induced Tissue Regeneration,” he will put in perspective his previous work on the immortalizing enzyme designated telomerase, pluripotent stem cell and reprogramming technology, and the emerging field of induced tissue regeneration (iTRTM) for future interventions in the biology of human aging. BioTime, together with its collaborator Insilico Medicine, previously announced a collaboration on an artificial intelligence (AI)-driven resource designed to facilitate the discovery of iTR-based treatments that could enable the body to repair tissue damage, without scarring. In his presentation, Dr. West will describe the biological basis of this new technology, being led by BioTime.

Dr. West will deliver the presentation on Thursday, December 8, from 4:15 p.m. to 5:15 p.m. EST in the Grand Ballroom of the Palm Beach County Convention Center. It will be live-streamed on the World Stem Cell Summit website and posted to BioTime’s YouTube channel in the days following the event.

Additionally, Dr. West will serve on a panel, “Unleashing Regenerative Medicine to Extend the Healthy Lifespan: Technological Issues and Commercial Opportunities,” on December 8 at 11:00 a.m. EST.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005838/en/

Investor Contact:EVC Group, Inc.Matt Haines, [e-mail] Contact:Gotham Communications, LLCBill Douglass, [e-mail]